Julia Netylko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Netylko has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra S. Anisimova
ГБУЗ «Городская клиническая больница им. И.В. Давыдовского Департамента здравоохранения г. Москвы», Москва, Российская Федерация
1 shared publication - Alexander V. Shpektor
Yevdokimov Moscow State University of Medicine and Dentistry
1 shared publication - Amanda Gwee
Department of Paediatrics The University of Melbourne Melbourne Victoria Australia
1 shared publication - Andreas Halman
Cancer Therapies Group Murdoch Children's Research Institute Parkville Australia
1 shared publication - Anna Kalinskaya
City Clinical Hospital No. 23 of Moscow Health Care Department, 109004 Moscow, Russia
1 shared publication - Claire Moore
Murdoch Children’s Research Institute, Melbourne, Australia
1 shared publication
Latest Publications
- 10 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70370
Tacrolimus in Pediatric Solid Organ Transplant Recipients: A Retrospective Cohort Study
Background: Tacrolimus is an effective immunosuppressant used after transplantation to prevent organ rejection. Standard tacrolimus dosing relies on therapeutic drug monitoring and does not account for patient‐specific factors, contributing to substantial inter‐individual variability. In this retrospective study, tacrolimus target attainment and intra‐patient variability under standard care were investigated in pediatric solid organ transplant recipients. Methods: In a cohort of 39 kidney, 31 liver, 48 heart, and 1 liver‐kidney transplant recipients, tacrolimus trough concentrations from days 4 to 56 post‐initiation of tacrolimus were analyzed. T ime in target range (TTR) and intra‐patient variability (coefficient of variation) were calculated over the 8‐week period. Secondary outcome analyses examined associations between TTR and clinical outcomes. Results: Across all groups, target attainment was lowest on day 4 and improved by days 21 and 56, but remained suboptimal, particularly among liver recipients (day 56: Heart 45%, kidney 76%, liver 31%). Average TTR was highest in the kidney (60%) and lowest in the liver recipients (27%), with only 3% of liver recipients spending at least half of the time within the target. Conclusions: Standard tacrolimus dosing often results in out‐of‐target exposure, with particularly poor target attainment and high variability among pediatric liver transplant recipients. These findings highlight the limitations of current approaches and support the need for more individualized strategies, including genotype‐guided dosing, to improve target attainment and outcomes in pediatric transplant recipients.
- 10 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (6) , e70370
Tacrolimus in Pediatric Solid Organ Transplant Recipients: A Retrospective Cohort Study
Background: Tacrolimus is an effective immunosuppressant used after transplantation to prevent organ rejection. Standard tacrolimus dosing relies on therapeutic drug monitoring and does not account for patient‐specific factors, contributing to substantial inter‐individual variability. In this retrospective study, tacrolimus target attainment and intra‐patient variability under standard care were investigated in pediatric solid organ transplant recipients. Methods: In a cohort of 39 kidney, 31 liver, 48 heart, and 1 liver‐kidney transplant recipients, tacrolimus trough concentrations from days 4 to 56 post‐initiation of tacrolimus were analyzed. T ime in target range (TTR) and intra‐patient variability (coefficient of variation) were calculated over the 8‐week period. Secondary outcome analyses examined associations between TTR and clinical outcomes. Results: Across all groups, target attainment was lowest on day 4 and improved by days 21 and 56, but remained suboptimal, particularly among liver recipients (day 56: Heart 45%, kidney 76%, liver 31%). Average TTR was highest in the kidney (60%) and lowest in the liver recipients (27%), with only 3% of liver recipients spending at least half of the time within the target. Conclusions: Standard tacrolimus dosing often results in out‐of‐target exposure, with particularly poor target attainment and high variability among pediatric liver transplant recipients. These findings highlight the limitations of current approaches and support the need for more individualized strategies, including genotype‐guided dosing, to improve target attainment and outcomes in pediatric transplant recipients.
- 31 July 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (7) , 31-37
The state of platelet and plasma hemostasis as a predictor of coronary blood flow in patients with acute myocardial infarction
Aim To study the relationship of the platelet function and plasma homeostasis with the blood flow in the infarct-related artery (IRA) and with the course of acute myocardial infarction (AMI). Material and methods This study included 93 patients with AMI (75 patients with ST-elevation AMI and 18 patients without ST segment elevation). 63 patients had TIMI 0-1 blood flow in the IRA and 30 patients had TIMI 2–3. Rotational thromboelastometry, impedance aggregometry, the endothelium-dependent vasodilation (EDVD) test, and the thrombodynamics test were performed for all patients. The primary clinical endpoint included the totality of in-hospital complications of AMI, and the secondary endpoint included the totality of out-of-hospital complications of AMI. Major bleedings (BARC 3-5) and minor bleedings (BARC 1-2) were evaluated separately. Results Patients with IRA TIMI 0–1 flow were characterized by a shorter blood clotting time (BCT), larger thrombus size and density, more intense platelet aggregation induced by arachidonic acid and ADP, and lower values of the EDVD test. It was found that the parameters of platelet aggregation induced by arachidonic acid (AUC Asa) in combination with BCT allowed assessment of the severity of IRA blood flow disorder (sensitivity 76 %, specificity 71 %) in patients with AMI, regardless of the presence of ST segment elevation on the ECG. In addition, the incidence of the primary endpoint was greater in patients with IRA TIMI 0–1 flow (41.3% and 16.7%, respectively; p=0.015). In patients with TIMI 2–3 flow in the long-term period of the disease, the incidence of minor bleedings was significantly higher (8.5% and 30.4 %, respectively; p=0.045). Conclusion Compared to patients with preserved blood flow, patients with AMI and IRA TIMI 0–1 flow are characterized by endothelial dysfunction and more intense processes of thrombogenesis and platelet aggregation. It has been shown for the first time that the combination of two simple criteria for assessing hemostasis (AUC Asa; BCT) allows assessment of the degree of IRA blood flow disorder in patients with AMI.
- 31 July 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (7) , 31-37
The state of platelet and plasma hemostasis as a predictor of coronary blood flow in patients with acute myocardial infarction
Aim To study the relationship of the platelet function and plasma homeostasis with the blood flow in the infarct-related artery (IRA) and with the course of acute myocardial infarction (AMI). Material and methods This study included 93 patients with AMI (75 patients with ST-elevation AMI and 18 patients without ST segment elevation). 63 patients had TIMI 0-1 blood flow in the IRA and 30 patients had TIMI 2–3. Rotational thromboelastometry, impedance aggregometry, the endothelium-dependent vasodilation (EDVD) test, and the thrombodynamics test were performed for all patients. The primary clinical endpoint included the totality of in-hospital complications of AMI, and the secondary endpoint included the totality of out-of-hospital complications of AMI. Major bleedings (BARC 3-5) and minor bleedings (BARC 1-2) were evaluated separately. Results Patients with IRA TIMI 0–1 flow were characterized by a shorter blood clotting time (BCT), larger thrombus size and density, more intense platelet aggregation induced by arachidonic acid and ADP, and lower values of the EDVD test. It was found that the parameters of platelet aggregation induced by arachidonic acid (AUC Asa) in combination with BCT allowed assessment of the severity of IRA blood flow disorder (sensitivity 76 %, specificity 71 %) in patients with AMI, regardless of the presence of ST segment elevation on the ECG. In addition, the incidence of the primary endpoint was greater in patients with IRA TIMI 0–1 flow (41.3% and 16.7%, respectively; p=0.015). In patients with TIMI 2–3 flow in the long-term period of the disease, the incidence of minor bleedings was significantly higher (8.5% and 30.4 %, respectively; p=0.045). Conclusion Compared to patients with preserved blood flow, patients with AMI and IRA TIMI 0–1 flow are characterized by endothelial dysfunction and more intense processes of thrombogenesis and platelet aggregation. It has been shown for the first time that the combination of two simple criteria for assessing hemostasis (AUC Asa; BCT) allows assessment of the degree of IRA blood flow disorder in patients with AMI.